GH Research PLC (NASDAQ:GHRS - Get Free Report) rose 3.1% on Monday . The stock traded as high as $9.05 and last traded at $8.88. Approximately 18,510 shares were traded during trading, a decline of 77% from the average daily volume of 79,195 shares. The stock had previously closed at $8.61.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reissued a "market outperform" rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th.
Get Our Latest Research Report on GHRS
GH Research Trading Up 8.0 %
The firm has a 50 day moving average price of $7.76 and a 200-day moving average price of $10.42. The firm has a market cap of $483.86 million, a price-to-earnings ratio of -13.25 and a beta of 0.74.
GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, equities analysts expect that GH Research PLC will post -0.85 earnings per share for the current fiscal year.
Institutional Investors Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. raised its holdings in GH Research PLC (NASDAQ:GHRS - Free Report) by 11.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 6,251,714 shares of the company's stock after acquiring an additional 664,381 shares during the period. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 at the end of the most recent reporting period. 56.90% of the stock is owned by institutional investors and hedge funds.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
